IGFBP2 and systemic sclerosis: Furthermore, baseline level of IGFBP-2 was elevated in the subgroup of SSc patients with lower variation of IGFBP-2 (less than 22%) compared the ones with higher variation of IGFBP-2 (more than 22%) (Fig. 4d).